Bortezomib-resistant nuclear factor-κB activity in multiple myeloma cells

Molecular Cancer Research

Volumn 6, Issue 8, 2008, Pages 1356-1364

  Markovina, Stephanie ^a   Callander, Natalie S ^a,b   O'Connor, Shelby L ^a   Kim, Jihoon ^a   Werndli, Jae E ^a   Raschko, Martha ^a   Leith, Catherine P ^a,b   Kahl, Brad S ^a,b   Kim, KyungMann ^a,b   Miyamoto, Shigeki ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; BORONIC ACID DERIVATIVE; ENZYME INHIBITOR; GREEN FLUORESCENT PROTEIN; PROTEASOME; PYRAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; STROMA CELL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; PATHOLOGY; REPORTER GENE; TUMOR CELL LINE;

APOPTOSIS; BONE MARROW CELLS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; STROMAL CELLS;

EID: 52449135431     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0108     Document Type: Article

References (42)

1. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62.
2. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
4. Baghdiguian S, Richard I, Martin M, et al. Pathophysiology of limb girdle muscular dystrophy type 2A: hypothesis and new insights into the IκBα/NF-κB survival pathway in skeletal muscle. J Mol Med 2001;79:254-61.
5. Cogswell PC, Kashatus DF, Keifer JA, et al. NF-κB and IκBα are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-κB. J Biol Chem 2003;278:2963-8.
6. Fan C, Li Q, Ross D, Engelhardt JF. Tyrosine phosphorylation of IκBα activates NFκB through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. J Biol Chem 2003;278:2072-80.
7. Kato T, Jr., Delhase M, Hoffmann A, Karin M. CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response. Mol Cell 2003;12:829-39.
8. Lee FY, Kim DW, Karmin JA, et al. μ-Calpain regulates receptor activator of NF-κB ligand (RANKL)-supported osteoclastogenesis via NF-κB activation in RAW 264.7 cells. J Biol Chem 2005;280:29929-36.
9. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Cancer Res 2002;62:6770-8.
10. Schaecher K, Goust JM, Banik NL. The effects of calpain inhibition on IκBα degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem Res 2004;29:1443-51.
11. Shen J, Channavajhala P, Seldin DC, Sonenshein GE. Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IκBα. J Immunol 2001;167:4919-25.
12. Berchtold CM, Chen KS, Miyamoto S, Gould MN. Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-κB pathway. Cancer Res 2005;65:8558-66.
13. Shumway SD, Miyamoto S. A mechanistic insight into a proteasome- independent constitutive inhibitor κBα (IκBα) degradation and nuclear factor κB (NF-κB) activation pathway in WEHI-231 B-cells. Biochem J 2004;380:173-80.
14. Yao T, Cohen RE. Giant proteases: beyond the proteasome. Curr Biol 1999;9:R551-3.
15. O'Connor S, Markovina S, Miyamoto S. Evidence for a phosphorylation- independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IκBα degradation in B cells. Exp Cell Res 2005;307:15-25.
16. O'Connor S, Shumway SD, Amanna IJ, Hayes CE, Miyamoto S. Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IκBα degradation in B cells. Mol Cell Biol 2004;24:4895-908.
17. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
18. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4.
19. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86.
20. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:30-6.
21. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
22. Anderson KC. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 2007;35:155-62.
23. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-98.
24. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103:3175-84.
25. Podar K, Hideshima T, Chauhan D, Anderson KC. Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin Ther Targets 2005;9:359-81.
26. Gregoretti MG, Gottardi D, Ghia P, et al. Characterization of bone marrow stromal cells from multiple myeloma. Leuk Res 1994;18:675-82.
27. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
28. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30.
29. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007;12:131-44.
30. Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma. Clin Exp Med 2007;7:83-97.
31. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-71.
32. Ehebauer M, Hayward P, Martinez-Arias A. Notch signaling pathway. Sci STKE 2006;2006:cm7.
33. Hunter T, Karin M. The regulation of transcription by phosphorylation. Cell 1992;70:375-87.
34. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999;3:169-79.
35. Wei W, Yu XD. Hypoxia-inducible factors: crosstalk between their protein stability and protein degradation. Cancer Lett 2007;257:145-56.
36. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle 2005;4:290-6.
37. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 2005;434:1138-43.
38. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003;12:1413-26.
39. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-κB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007;8:584-91.
40. Dolcet X, Llobet D, Encinas M, et al. Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006;281:22118-30.
41. Nagy K, Szekely-Szuts K, Izeradjene K, et al. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathol Oncol Res 2006;12:133-42.
42. 2-M arrest by nuclear factor-κB-dependent p21waf1/cip1 induction. Mol Cancer Res 2005;3:345-53.